Abbreviated Name

LTP2

Lead Investigator

Lenburg, Marc — Boston University

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Herman, James — University of Pittsburgh School of Medicine
• Huflejt, Margaret E. — New York University School of Medicine
• Crichton, Dan — NASA Jet Propulsion Laboratory
• Schabath, Matthew — H. Lee Moffitt Cancer Center & Research Institute, Inc.
• Stass, Sanford — University of Maryland School of Medicine
• Lenburg, Marc — Boston University
• Grogan, Eric — Vanderbilt -Ingram Cancer Center
• Willey, James — University of Toledo College of Medicine
• Sidransky, David — Johns Hopkins University
• Vuskovic, Marko — San Diego State University
• Pass, Harvey Ira — New York University School of Medicine
• Lamb, Carla — Lahey Hospital and Medical Center
• Spira, Avrum — Boston University
• Diaz-Mayoral, Norma — Frederick National Laboratory for Cancer Research
• Srivastava, Sudhir — National Cancer Institute
• Dubinett, Steve — University of California Los Angeles
• Rom, William — New York University School of Medicine

Abstact

To characterize intra or within subject reproducibility and variability To characterize inter or across subject variability by adenoma phenotype (normal vs. adenoma) To evaluate biomarker expression in relation to long term adenoma recurrence

Aims

3.1.1   Aim 1 Establish a cohort (n=200) of current and former smokers with indeterminate pulmonary nodules (7mm-25mm) on whom clinical, radiographic and biospecimen repositories are developed and who are followed prospectively until final diagnosis. 3.1.2   Aim 2 Validate the diagnostic accuracy of existing molecular biomarkers in the airway and blood to detect lung cancer in this clinical cohort.

Analytic Method

Airway gene-expression biomarker (BU) Airway protein biomarker (VU): LC-MRM-MS analyses Serum glycan biomarker (NYU): Plasma promoter methylation biomarker (JHU): Serum cytokines biomarker (UCLA): Serum/Plasma miRNA biomarker (OSU): Plasma miRNA biomarker (UMD):

Outcome

To characterize intra or within subject reproducibility and variability To characterize inter or across subject variability by adenoma phenotype (normal vs. adenoma) To evaluate biomarker expression in relation to long term adenoma recurrence

Publications

• No publications available at this time for this protocol.

Biomarkers

• Bronchial proteomic biomarkers (50)
• CDO1 methylation loci
• CEA (by CBSI from serum)
• CYFRA 21.1 (by CBSI from serum)
• Gene-expression profile (RNA and DNA from nasal and bronchial brushings)
• HE4 (by CBSI from serum)
• HOXA7 methylation loci
• LCP-CNN model (CT-images)
• LFAMB (5 loci in three gene regions of RNA and DNA from nasal and bronchial brushings)
• miRNA profile (plasma)
• NanoString Panel (539 gene-expression probes)
• Radiomic signature (CT-images)
• Serum based quantitation of CYFRA 21.1, CEA and HE4
• SOX17 methylation loci
• TAC1 methylation loci

Data Collections

There is one collection of data that has not yet been made public. Logging in may you give you access to the names of the non-public data collections.

 Team Project

Start Date

Mar 8 2012

Estimated Finish Date

Mar 7 2015

Protocol ID

354

Protocol Type

Validation

Field of Research

Genomics

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

2